A Study of LY3314814 in Healthy Participants

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: LY3314814; Drug: [13C415N3] LY3314814

Study type: Interventional

Funder types: Industry

Identifiers

NCT03222427

2017-001181-18 (EudraCT Number)

I8D-MC-AZEP (Other Identifier)

15993

Details and patient eligibility

About

The purpose of this study is to measure how much LY3314814 gets into the bloodstream when it is given as a single dose by mouth and as an intravenous (IV) infusion over two hours. The study will last at least two weeks for each participant, not including screening.

Enrollment: 8 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Are overtly healthy males or females
• Have venous access sufficient to allow for blood sampling and intravenous (IV) administration of the investigational product

Exclusion criteria

• Have a history of significant ophthalmic disease
• Have vitiligo or any other clinically significant disorder of skin pigmentation
• Have a history of use of antipsychotic drugs, or chronic use of antidepressant or anxiolytic drugs, prescribed as well as non-prescribed

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

8 participants in 2 patient groups

LY3314814

Experimental group

Description:

Single 50 milligram (mg) dose of LY3314814 administered orally

Treatment:

Drug: LY3314814

[13C415N3] LY3314814

Experimental group

Description:

Single 100 micrograms (μg) intravenous (IV) dose of \[13C415N3\] LY3314814 administered as an IV infusion.

Treatment:

Drug: [13C415N3] LY3314814